Combigan

/ AbbVie

One drop in the affected eye(s) twice a day (± every 12 hours).
If using more than one topical ophthalmic solution, use 10 minutes apart.

For the control of intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to IOP reducing monotherapy and when the use is considered appropriate.

Hypersensitivity to brimonidine tartrate, timolol maleate or any non-medicdbinal ingredient of this medicdbation. Patients with bronchial asthma or a history thereof. Severe chronic obstructive pulmonary disease, sinus bradycardia, second- or third-degree atrioventricular block, overt cardiac failure, cardiogenic shock, patients receiving MAOI therapy.

Should be used with caution in patients with known hypersensitivity to other alpha-adrenoceptor agonists. If signs of serious reactions or hypersensitivity occur, discontinue. Beta-adrenergic blockade has been reported to increase muscle weakness consistent with certain myasthenic symptoms. Timolol maleate has been reported (rarely) to increase muscle weakness in some patients with myasthenia gravis or myasthenia symptoms. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. Cardiac failure should be adequately controlled before beginning therapy. In patients with a history of severe cardiac disease, signs of cardiac failure should be watched for and pulse rates should be checked. Patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemia agents. Should not be used alone in the treatment of acute angle-closure glaucoma. The use in pediatric patients is currently not recommended. Patients prescribed IOP-lowering medicdbation should be routinely monitored for IOP. Should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension or thromboangitis obliterans. Should not be administered while wearing soft contact lenses and new lenses should not be reinserted earlier than 15 minutes after use. Choroidal detachment after filtration procedures have been reported. Management of eyes with chronic or recurrent choroidal detachment should include stopping all forms of aqueous suppressant therapy and treating endogenous inflammation vigorously. Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of the beta-adrenergic blocking agents that might precipitate a thyroid storm. Should be used with caution in patients with cerebrovascular insufficiency. Has not been studied in patients with hepatic or renal impairment. Patients who engage in hazardous activities should be cautioned of the potential for a decrease in mental alertness. Pregnancy and lactation:Should be used during pregnancy only if the potential benefit to the mother justifices the potential risk to the fetus. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
See prescribing information for full details.

Conjunctival hyperemia, burnign sensation in eye.
See prescribing information for full details.

Antihypertensives and/or cardiac glycosides. Oral calcium channel blockers, catecholamine-depleting drugs such as reserpine, or beta-adrenergic blocking agents. CNS depressants, epinephrine, quinidine, tricyclic antidepressants. Patients who are receiving a beta-adrenergic blocking agent orally concomitantly, should be observed for potential additive effects of beta-blockade. The concomitant use of two topical beta-adrenergic blocking agents is not recommended.
See prescribing information for full details.